The bill should be supported because it reinforces transparency and accountability in government actions related to public health. By preventing future indemnities to vaccine manufacturers, the bill ensures that pharmaceutical companies are responsible for their products, which can lead to more responsible behavior and better safety standards in vaccine development. This aligns with the principles of a representative democracy where the public has the right to scrutinize government decisions, especially those involving public health and financial liabilities [Judgment]. Additionally, it reduces the financial burden on taxpayers who would otherwise shoulder potential liabilities from vaccine-related injuries or claims.
The bill should be opposed because it might deter pharmaceutical companies from supplying vaccines to Australia, particularly in urgent public health situations like pandemics. The availability of indemnities can be a critical factor in securing rapid access to vaccines, as it reduces the financial risk for manufacturers. Without such indemnities, companies may prioritize other markets where their financial exposure is limited, potentially delaying vaccine availability in Australia. This could undermine public health efforts and national security by limiting the country's ability to respond swiftly to health crises [Judgment]. Furthermore, the removal of indemnities might increase the cost of vaccines, as manufacturers may raise prices to offset increased risk.
2023-08-03
Before Senate
BABET, Sen Ralph
Unspecified
Anti-Corruption, Health, National Security